Early Bird Health Economics (EBHE) sets out how AbbVie is helping to
secure better outcomes for patients, and a sustainable NHS, through a
focus on the benefits of early interventions and access to treatment.
This spans multiple different issues, from approval processes through
to diagnosis and funding. The common thread through all is that a
focus on getting patients access to the latest treatments at the right
time and ensuring it can be done sustainably, will both be better for
patients and for the NHS.
With the NHS facing complex challenges, its primary goal is to
achieve the best health outcomes it can from the resources it has,
whilst remaining free at the point of delivery.
Due to the NHS’s finite resources, it is crucial that value is at
the heart of its decision making – ensuring decisions are practical
and sustainable whilst also maximising the benefits for patients and populations.
AbbVie supports the aims of the NHS Long Term Plan, continuing to
work as a partner in providing innovative solutions to ensure outcomes
improve for patients, especially in areas such as HCV, cancer,
immunology and respiratory care.
Within oncology, through innovative partnering and collaboration, we
are supporting the EBHE initiative by intelligent use of data. For
example, AbbVie are part of one of the largest efforts to create human
genetic data – the sequencing of the genes of 500,000 volunteers from
the United Kingdom by a consortium of pharmaceutical companies. With
earlier diagnosis not only saving the lives of thousands of patients
each year, a more targeted screening processes will also improve the
allocation of NHS cancer resources.1
We are also proud to be piloting early innovation for
musculoskeletal conditions. Amongst the pilot projects we support is
the UK’s first early intervention clinic for people signed off work
with a musculoskeletal condition. It reduces waits for specialist
referral from weeks to days and is informing the commissioning of a
new MSK pathway by CCGs in Leeds.2
With such conditions placing a major health burden on the UK
population, improvement in access to early interventions for patients
means better treatment, reduced risk of co-morbidities, increased
self- management of the condition as well as a larger number of
patients likely to stay in or return to work.